Search Results (2)

Six N^C^N cyclometalated Ni(II) complexes [Ni(N^C^N)Cl] or [Ni(N^C^N’)Br] with symmetric N^C^N or non-symmetric N^C^N’ ligands in which the peripheral N-groups were varied with pyridine (Py), 4-thiazole (4Tz), 2-thiazole (2Tz), and 2-benzothiazole (2Btz) complementing the previously reported complexes with di(2-pyridyl)phenide ligands [Ni(Py(Ph)Py)X] X = Cl or Br. The non-symmetric [Ni(N^C^N’)Br] complexes were synthesized from NiBr₂ and N^CH^N’ protoligands through base-assisted nickelation, while the symmetric [Ni(N^C^N)Cl] complexes were received from the N^C(Cl)^N protoligands and [Ni(COD)₂] (COD = 1,5-cyclooctadiene). Introduction of 4Tz on both sides shifted the electrochemical gap ΔE_exp = E_ox–E_red and the long wavelength UV-vis absorption maxima of the complexes to higher energies, while 2Tz leads to a shift to lower energies. When introducing only one 4Tz or 2Tz as peripheral groups, the remaining PhPy moiety dominates the electronic properties and electrochemistry and photophysics are very similar to the Py(Ph)Py derivatives. In contrast to this, introduction of 2Btz shifts both values to lower energies, regardless of one or two 2Btz groups and the 2Btz moiety dominates the character of the frontier molecular orbitals of the complexes, as DFT calculations show. Long-wavelength UV-vis absorptions vary from 416 to 443 nm, and their energies correlate well with the first reduction potentials. Negishi-type C–C cross-coupling reactions gave total yields ranging from 1 to 60% and cross-coupling yields from 1 to 44%. The reactivities correlate roughly with the first reduction potentials. Facilitated reduction (E around –2 or higher) goes generally along with improved performance, making the thiazole-containing complexes interesting candidates for such catalysis. Full article

The 1,3-benzothiazole (BTZ) ring may offer a valid option for scaffold-hopping from indole derivatives. Several BTZs have clinically relevant roles, mainly as CNS medicines and diagnostic agents, with riluzole being one of the most famous examples. Riluzole is currently the only approved drug to treat amyotrophic lateral sclerosis (ALS) but its efficacy is marginal. Several clinical studies have demonstrated only limited improvements in survival, without benefits to motor function in patients with ALS. Despite significant clinical trial efforts to understand the genetic, epigenetic, and molecular pathways linked to ALS pathophysiology, therapeutic translation has remained disappointingly slow, probably due to the complexity and the heterogeneity of this disease. Many other drugs to tackle ALS have been tested for 20 years without any success. Dexpramipexole is a BTZ structural analog of riluzole and was a great hope for the treatment of ALS. In this review, as an interesting case study in the development of a new medicine to treat ALS, we present the strategy of the development of dexpramipexole, which was one of the most promising drugs against ALS. Full article